The peptide is stable with a moderate half-life allowing once-daily dosing
BPC-157 modulates cytokine production, lowering pro-inflammatory signals (IL-6, TNF-alpha) while preserving or enhancing anti-inflammatory responses
Its effects stay focused on adipose tissue: AOD9604 stimulates lipolysis primarily through beta3 adrenergic receptor pathways in adipose tissue, driving the breakdown of stored triglycerides into free fatty acids
Metformin, a first-line biguanide, reduces hepatic glucose production, while tirzepatidea dual GIP/GLP-1 receptor agonist approved by the FDA in 2022enhances insulin secretion, suppresses glucagon, and promotes weight loss
Every client begins with a personalized consultation to assess their wellness needs, medical history, and lifestyle, allowing us to build a custom protocol that delivers safe and effective results
Do it well, and peptide therapy can be a real growth driver for your clinic